Work

Off-label use of rituximab in systemic rheumatic diseases: case series and review.

Year: 2013
Type: article
Study design: Case Report
Abstract: B-cells play an important role not only in cellular but also in humoral immunity through differentiation into plasma cells and antibody production. B-cell depletion may, theoretically, change the course of systemic rheumatic diseases (SRD) in which self-reactive antibodies are part of the pathogenic pathway. In Rheumatology, anti-B-cell antibody Rituximab is currently licensed for the treatment of rheumatoid arthritis, however there is growing evidence of its potential use in other SRD. The authors present a case series of eight patients in which Rituximab was used off-label including overlap syndrome Rhupus, systemic lupus erythematosus and Wegener's granulomatosis. In the end, a brief literature review about this subject is performed.
Source: PubMed
Language: English
Subfield: Rheumatology
Field: Medicine
Open Access status: green
OpenAlex ID: W38808979
FWCI: 0.216
Cites: 1
Cited by: 7
Related to: 10